WeLeader Biomedical Co., Ltd. (TPEX:7713)
Taiwan
· Delayed Price · Currency is TWD 69.50
-0.70 (-1.00%)
At close: Mar 9, 2026
WeLeader Biomedical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | 208.56 | 170.21 | 152.28 | 153.8 | 105.77 |
| Depreciation & Amortization | 124.16 | 108.58 | 103.8 | 109.82 | 114.44 |
| Loss (Gain) From Sale of Assets | - | 0.02 | 1.69 | -0.69 | -0.41 |
| Asset Writedown & Restructuring Costs | -0.09 | - | - | - | - |
| Loss (Gain) From Sale of Investments | -0.15 | -0.4 | -0.1 | 0.68 | -0.01 |
| Stock-Based Compensation | 1.61 | - | 0.18 | 4.23 | 3.65 |
| Provision & Write-off of Bad Debts | -0.1 | 0.06 | -0.48 | -0.53 | 0.39 |
| Other Operating Activities | -0.5 | -6.84 | -19.56 | 8.41 | 12.49 |
| Change in Accounts Receivable | -46.63 | -5.75 | -3.17 | 21.59 | -47.61 |
| Change in Inventory | -18.78 | -29.81 | -5.77 | -7.1 | -13.37 |
| Change in Accounts Payable | 30.87 | 40.35 | -12.09 | -5.37 | 43.39 |
| Change in Unearned Revenue | - | 1.19 | -0.36 | -1.25 | 1.02 |
| Change in Other Net Operating Assets | 14.36 | 1.14 | 15.43 | -3.3 | 18.27 |
| Operating Cash Flow | 313.3 | 278.76 | 231.86 | 280.27 | 238.03 |
| Operating Cash Flow Growth | 12.39% | 20.23% | -17.27% | 17.75% | - |
| Capital Expenditures | -212.74 | -170.71 | -114.73 | -659.36 | -21.6 |
| Sale of Property, Plant & Equipment | - | - | 0.95 | 1.06 | 0.42 |
| Sale (Purchase) of Intangibles | -1.01 | -3.56 | -1 | -2.29 | -2.3 |
| Investment in Securities | -61.66 | -22.39 | 0.83 | -4.68 | 20.77 |
| Investing Cash Flow | -275.4 | -196.65 | -113.96 | -665.28 | -2.71 |
| Short-Term Debt Issued | 80 | 79 | 224 | 247 | 53 |
| Long-Term Debt Issued | 625.01 | 193.13 | - | 291 | 20 |
| Total Debt Issued | 705.01 | 272.13 | 224 | 538 | 73 |
| Short-Term Debt Repaid | -160 | -56 | -288.03 | -178.97 | -122 |
| Long-Term Debt Repaid | -605.21 | -122.33 | -91.64 | -118.66 | -154.6 |
| Total Debt Repaid | -765.21 | -178.33 | -379.67 | -297.63 | -276.6 |
| Net Debt Issued (Repaid) | -60.21 | 93.8 | -155.67 | 240.37 | -203.6 |
| Issuance of Common Stock | 238.2 | - | 61.48 | 143.64 | - |
| Common Dividends Paid | -153.17 | -95.63 | -29.75 | -9.77 | -22.36 |
| Other Financing Activities | 0.02 | - | - | -0.02 | - |
| Financing Cash Flow | 24.85 | -1.83 | -123.94 | 374.22 | -225.96 |
| Net Cash Flow | 62.74 | 80.28 | -6.03 | -10.79 | 9.35 |
| Free Cash Flow | 100.56 | 108.06 | 117.13 | -379.09 | 216.43 |
| Free Cash Flow Growth | -6.94% | -7.75% | - | - | - |
| Free Cash Flow Margin | 9.06% | 10.90% | 12.45% | -36.60% | 25.73% |
| Free Cash Flow Per Share | 2.18 | 2.59 | 2.85 | -12.46 | 7.70 |
| Cash Interest Paid | - | 14.94 | 13.6 | 6.42 | 6.31 |
| Cash Income Tax Paid | - | 43.1 | 51.74 | 28.44 | 11.83 |
| Levered Free Cash Flow | -48.2 | 67.88 | 106.57 | -412.67 | - |
| Unlevered Free Cash Flow | -43.19 | 71.51 | 110.13 | -410.04 | - |
| Change in Working Capital | -20.19 | 7.12 | -5.95 | 4.56 | 1.7 |
Source: S&P Capital IQ. Standard template. Financial Sources.